GlassScriptPhysician profile
Marshall Bedine
NPI 1194719658
$8,008.57
in general payments reported to CMS, 2019-2025
36 companies · $2,027 in 2025
The $2,027 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $288 · 2021: $446 · 2022: $1,097 · 2023: $1,816 · 2024: $2,024 · 2025: $2,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,786 · Gift: $81.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,785.56 |
| Gift | $81.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,666.39 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,278.67 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $690.84 | 2021-2025 | |
| Janssen Biotech, INC. | $560.14 | 2019-2024 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $398.43 | 2023-2025 | Xifaxan, Trulance |
| Braintree Laboratories, INC. | $366.77 | 2019-2023 | Suflave, Sutab |
| Daiichi Sankyo INC. | $235.04 | 2020-2024 | Injectafer |
| Celgene Corporation | $211.56 | 2022-2024 | Zeposia |
| Celltrion USA INC. | $113.76 | 2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $110.56 | 2024-2025 | Iqirvo |
| Organon LLC | $101.35 | 2022-2024 | Hadlima, Renflexis |
| Aimmune Therapeutics, INC. | $98.37 | 2023-2024 | |
| Allergan, INC. | $91.48 | 2019 | |
| Genzyme Corporation | $90.34 | 2024-2025 | |
| Ardelyx, INC. | $84.95 | 2023-2025 | Ibsrela |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $81.25 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.54 | 2023-2024 | Cyltezo |
| Madrigal Pharmaceuticals | $76.52 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $73.45 | 2023-2024 | Dificid, Zinplava |
| Lilly USA, LLC | $68.19 | 2024-2025 | Omvoh |
| Mallinckrodt Hospital Products INC. | $60.24 | 2024-2025 | Terlivaz |
| Qol Medical, LLC | $56.91 | 2024-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $47.82 | 2025 | |
| Intercept Pharmaceuticals, INC. | $47.29 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $42.32 | 2023 | Linzess |
| Amgen INC. | $42.12 | 2025 | Uplizna |
| Shield Therapeutics INC | $41.65 | 2022-2025 | |
| Sandoz INC. | $31.68 | 2025 | Hyrimoz |
| Biocon Biologics INC | $25.20 | 2025 | Yesintek |
| Ferring Pharmaceuticals INC. | $24.60 | 2025 | Rebyota |
| Orphalan INC | $22.75 | 2025 | Cuvrior |
| Fresenius Kabi USA, LLC | $22.71 | 2024 | Idacio |
| Alnylam Pharmaceuticals INC. | $17.83 | 2024 | Givlaari |
| Shire North American Group INC | $17.60 | 2019 | |
| Olympus America INC. | $15.91 | 2019 | |
| Alfasigma USA, INC. | $15.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Bedine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.